- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00054067
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix
Treatment of Patients With Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemo-Radiation Versus Primary Chemo-Radiation
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of radiation therapy combined with chemotherapy, with or without surgery, is more effective in treating early cancer of the cervix.
PURPOSE: Randomized phase III trial to compare the effectiveness of surgery followed by different regimens of radiation therapy and chemotherapy with that of chemotherapy and radiation therapy alone in treating patients who have stage I cancer of the cervix.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
OBJECTIVES:
- Compare progression-free survival and survival of patients with stage IB2 carcinoma of the cervix after radical hysterectomy with tailored chemoradiotherapy vs primary chemoradiotherapy.
- Compare the toxicity of these regimens in these patients.
- Compare the health-related quality of life of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.
Arm I: (Surgery followed by chemoradiotherapy): Patients undergo exploratory laparotomy followed by radical hysterectomy and bilateral pelvic and para-aortic lymphadenectomy. Depending on the findings at surgery, the radical hysterectomy and lymphadenectomy are either completed or aborted.
Aborted hysterectomy: Patients with aborted hysterectomy are assigned to 1 of 3 groups, depending on the findings at surgery.
- Group 1: Within 4 weeks of surgery, patients undergo pelvic radiotherapy 5 times weekly for 4-6 weeks and intracavitary irradiation during or after external radiotherapy. Patients also receive concurrent cisplatin IV over 1 hour once weekly for a total of 5-6 doses.
- Group 2: Patients receive radiotherapy and cisplatin as in group 1 with additional extended field radiotherapy.
- Group 3: Patients receive further treatment at the discretion of the investigator.
Completed hysterectomy: Patients completing the radical hysterectomy are assigned to 1 of 3 groups, depending on the findings at surgery.
- Group A: Patients receive treatment as in group 1 above without intracavity irradiation.
- Group B: Patients receive treatment as in group 2 above without intracavity irradiation.
- Group C: Patients receive no further treatment.
- Arm II (Primary chemoradiotherapy): Patients undergo pelvic radiotherapy 5 times weekly for 4-6 weeks and intracavity irradiation during or after external radiotherapy. Patients also receive concurrent cisplatin IV over 1 hour once weekly for a total of 6 doses.
Quality of life is assessed at baseline, during week 5 of therapy, and then at 3, 6, and 12 months.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 740 patients (370 per treatment arm) will be accrued for this study within 7.5 years.
Studientyp
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
-
Kagoshima City, Japan, 892-8580
- Kagoshima City Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294-3300
- University of Alabama at Birmingham Comprehensive Cancer Center
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85006-2726
- CCOP - Western Regional, Arizona
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90095-1740
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Gatos, California, Vereinigte Staaten, 95032
- Women's Cancer Center at Community Hospital of Los Gatos
-
Orange, California, Vereinigte Staaten, 92868
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06520-8028
- Yale Comprehensive Cancer Center
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- CCOP - Christiana Care Health Services
-
-
District of Columbia
-
Washington, District of Columbia, Vereinigte Staaten, 20307-5001
- Walter Reed Army Medical Center
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60637-1470
- University of Chicago Cancer Research Center
-
Chicago, Illinois, Vereinigte Staaten, 60612
- MBCCOP - University of Illinois at Chicago
-
Chicago, Illinois, Vereinigte Staaten, 60612-3824
- Rush-Presbyterian-St. Luke's Medical Center
-
Decatur, Illinois, Vereinigte Staaten, 62794-9640
- CCOP - Central Illinois
-
Evanston, Illinois, Vereinigte Staaten, 60201
- CCOP - Evanston
-
Urbana, Illinois, Vereinigte Staaten, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202-5289
- Indiana University Cancer Center
-
South Bend, Indiana, Vereinigte Staaten, 46617
- Saint Joseph Regional Medical Center
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242-1002
- Holden Comprehensive Cancer Center at University of Iowa
-
-
Maryland
-
Bethesda, Maryland, Vereinigte Staaten, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- CCOP - Michigan Cancer Research Consortium
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- CCOP - Grand Rapids
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007-3731
- CCOP - Kalamazoo
-
-
Minnesota
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- CCOP - Metro-Minnesota
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216-4505
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65203
- Ellis Fischel Cancer Center at University of Missouri - Columbia
-
Kansas City, Missouri, Vereinigte Staaten, 64131
- CCOP - Kansas City
-
Springfield, Missouri, Vereinigte Staaten, 65807
- CCOP - Cancer Research for the Ozarks
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68106
- CCOP - Missouri Valley Cancer Consortium
-
-
New Jersey
-
Camden, New Jersey, Vereinigte Staaten, 08103-1489
- Cooper University Hospital
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Memorial Sloan-Kettering Cancer Center
-
Stony Brook, New York, Vereinigte Staaten, 11790-7775
- Long Island Cancer Center at Stony Brook University Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599-7295
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267-0526
- Charles M. Barrett Cancer Center at University Hospital
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Ireland Cancer Center
-
Columbus, Ohio, Vereinigte Staaten, 43210-1240
- Arthur G. James Cancer Hospital - Ohio State University
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97225
- CCOP - Columbia River Oncology Program
-
-
Pennsylvania
-
Abington, Pennsylvania, Vereinigte Staaten, 19001-3788
- Abington Memorial Hospital
-
Danville, Pennsylvania, Vereinigte Staaten, 17822-2001
- CCOP - Geisinger Clinic and Medical Center
-
Hershey, Pennsylvania, Vereinigte Staaten, 17033-0850
- Penn State Cancer Institute at Milton S. Hershey Medical Center
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104-4283
- Abramson Cancer Center at University of Pennsylvania Medical Center
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213-3180
- Magee-Womens Hospital
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37917
- Southeast Gynecologic Oncology Associates
-
Nashville, Tennessee, Vereinigte Staaten, 37232-2516
- Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
-
-
Texas
-
Galveston, Texas, Vereinigte Staaten, 77555-0587
- University of Texas Medical Branch
-
Houston, Texas, Vereinigte Staaten, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
Temple, Texas, Vereinigte Staaten, 76508
- CCOP - Scott and White Hospital
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05401
- Fletcher Allen Health Care - Medical Center Campus
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53792-6188
- University of Wisconsin Comprehensive Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
DISEASE CHARACTERISTICS:
Histologically confirmed stage IB2 invasive carcinoma of the uterine cervix of one of the following types:
- Squamous cell carcinoma
- Adenocarcinoma
- Adenosquamous carcinoma
- Primary, previously untreated disease
- Exophytic cervical lesions greater than 4 cm in diameter OR
- Cervical expansion to greater than 4 cm in diameter, presumed to be the result of principal involvement with cancer
- No evidence of extrauterine disease other than pelvic lymph node involvement (by clinical and radiographic examinations)
- No para-aortic lymph nodal disease (suspected on CT scan, MRI, positron-emission tomography, or lymphangiogram) unless nodes are confirmed to be pathologically negative (by CT-guided biopsy or extraperitoneal lymph node dissection)
- Eligible for radical hysterectomy and lymph node dissection
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- GOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 times normal
- SGOT no greater than 3 times normal
- Alkaline phosphatase no greater than 3 times normal
Renal
- Creatinine no greater than 2.0 mg/dL
- No renal abnormalities requiring modification of radiation fields
Gastrointestinal
- No gastrointestinal bleeding
- No intestinal obstruction
Other
- Not pregnant
- Negative pregnancy test
- No septicemia or severe infection
- No other invasive malignancy with any evidence of disease within the past 5 years except nonmelanoma skin cancer
- No circumstances that would preclude study completion or required follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior chemotherapy
Endocrine therapy
- Not specified
Radiotherapy
- No prior radiotherapy
Surgery
- See Disease Characteristics
- No prior hysterectomy (total or subtotal)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienstuhl: D. Scott McMeekin, MD, Oklahoma University Cancer Institute
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- CDR0000269821
- GOG-0201
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Gebärmutterhalskrebs
-
Tanta UniversityNoch keine RekrutierungSchilddrüsenchirurgie | Verbesserte Wiederherstellung | Bilateraler ultraschallgeführter oberflächlicher Plexus-Cervical-Block
-
Khon Kaen UniversityBeendetHumane Papillomavirus-Clearance nach 12 MonatenThailand
-
Orthofix Inc.AbgeschlossenDegenerative Bandscheibenerkrankungen | Vertebral Cervical Fusion SyndromeVereinigte Staaten
-
University Hospital, LinkoepingAhmed Mohamed Abdelrahman; Mahmoud Ahmed Mewafy; Abdelrhman Alshawadfy; Haidi Abd-Elzaher und andere MitarbeiterAbgeschlossenPostoperative Schmerzen | Analgesie durch lokale Wundinfiltration von Lidocain | Analgesie mit einer ultraschallgeführten Plexus-Cervical-Blockade unter Verwendung von LidocainSchweden
Klinische Studien zur Strahlentherapie
-
Alpha Tau Medical LTD.Noch keine RekrutierungBrustkrebs | Brustkrebs | Rezidivierender BrustkrebsIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Hauttumor | Kutane MetastasenFrankreich
-
Alpha Tau Medical LTD.European Organisation for Research and Treatment of Cancer - EORTCNoch keine RekrutierungKopf-Hals-Plattenepithelkarzinom | PlattenepithelkarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungProstata-AdenokarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael
-
Alpha Tau Medical LTD.RekrutierungLungenkrebs | Wiederkehrender LungenkrebsIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael
-
Alpha Tau Medical LTD.AbgeschlossenPlattenepithelkarzinomIsrael
-
Alpha Tau Medical LTD.RekrutierungHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaItalien
-
Alpha Tau Medical LTD.Aktiv, nicht rekrutierendHautkrebs | Schleimhautneoplasma der Mundhöhle | WeichteilneoplasmaIsrael